GARDP wants five AMR breakers by 2025
GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025.
Sanifit raise 72.2m to push SNF472 development
Sanifit has bagged 72.2m in Spains largest private biotech fundraise.
Genfit in $228m deal with Terns Pharmaceuticals
Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.
Vesalius Biocapital III Fund closes at 120 million
Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at 120m.
Erytech Pharma SA bags US$57m from SQZ Biotechnologies
Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies.
Sanofi/Regeneron’s IL-33 blocker meets endpoint in POC study
Sanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients.
Karo Pharma acquires Trimb AB
Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (141m).
GM proponents grill German government
German GM proponents have taken action against discrimination of food products generated by gene editing.
New CEO for Valo Therapeutics
Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the companys inception in 2017.
IL-10R-deficient macrophages trigger IBD
Researchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.